As of 2025-11-06, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -6.46. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 926.63 mil USD. URGN's TTM EBITDA according to its financial statements is -143.37 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 10.4x | 10.4x |
| Forward P/E multiples | 8.9x - 11.6x | 11.1x |
| Fair Price | (28.24) - (32.95) | (34.04) |
| Upside | -246.3% - -270.7% | -276.3% |
| Date | EV/EBITDA |
| 2025-11-05 | -6.46 |
| 2025-11-04 | -6.62 |
| 2025-11-03 | -6.89 |
| 2025-10-31 | -6.84 |
| 2025-10-30 | -6.64 |
| 2025-10-29 | -6.61 |
| 2025-10-28 | -6.74 |
| 2025-10-27 | -6.96 |
| 2025-10-24 | -6.35 |
| 2025-10-23 | -5.82 |
| 2025-10-22 | -5.93 |
| 2025-10-21 | -6.09 |
| 2025-10-20 | -6.04 |
| 2025-10-17 | -5.70 |
| 2025-10-16 | -5.70 |
| 2025-10-15 | -5.81 |
| 2025-10-14 | -5.60 |
| 2025-10-13 | -5.64 |
| 2025-10-10 | -5.61 |
| 2025-10-09 | -5.53 |
| 2025-10-08 | -5.82 |
| 2025-10-07 | -5.67 |
| 2025-10-06 | -5.73 |
| 2025-10-03 | -5.85 |
| 2025-10-02 | -5.74 |
| 2025-10-01 | -5.98 |
| 2025-09-30 | -6.67 |
| 2025-09-29 | -6.41 |
| 2025-09-26 | -6.15 |
| 2025-09-25 | -5.80 |
| 2025-09-24 | -6.04 |
| 2025-09-23 | -6.00 |
| 2025-09-22 | -6.04 |
| 2025-09-19 | -6.02 |
| 2025-09-18 | -6.32 |
| 2025-09-17 | -6.07 |
| 2025-09-16 | -6.06 |
| 2025-09-15 | -6.06 |
| 2025-09-12 | -6.30 |
| 2025-09-11 | -6.44 |
| 2025-09-10 | -6.40 |
| 2025-09-09 | -6.91 |
| 2025-09-08 | -7.14 |
| 2025-09-05 | -6.32 |
| 2025-09-04 | -6.30 |
| 2025-09-03 | -6.48 |
| 2025-09-02 | -6.53 |
| 2025-08-29 | -6.51 |
| 2025-08-28 | -6.44 |
| 2025-08-27 | -6.54 |